Alex Z Fu - JoVE Visualize

Showing results (81-90 of 87) with videos related to

Pageof 9

Sort By:

You have reached the last page of results.This site can display upto 87 results.

The Journal of Urology|December 24, 2016

Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate CancerAlex Z Fu, Huei-Ting Tsai, Reina Haque, et al.

Journal of the American College of Cardiology|June 2, 2018

SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REALMatthew A Cavender, Anna Norhammar, Kåre I Birkeland, et al.

Circulation|May 20, 2017

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, et al.

Hematological Oncology|April 10, 2025

Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta-AnalysisLucio N Gordan, Rohan Medhekar, Alex Z Fu, et al.

Diabetes, Obesity & Metabolism|March 24, 2018

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL studyMikhail Kosiborod, Kåre I Birkeland, Matthew A Cavender, et al.

Clinical Lymphoma, Myeloma & Leukemia|October 14, 2023

Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review StudyLucio Navarro Gordan, Carlyn Rose Tan, Robert Vescio, et al.

Neuro-Oncology|April 14, 2022

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trialAntonio Omuro, Alba A Brandes, Antoine F Carpentier, et al.

Pageof 9

Showing results (81-90 of 87) with videos related to

Sort By:

Pageof 9

You have reached the last page of results.This site can display upto 87 results.

The Journal of Urology|December 24, 2016

Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate CancerAlex Z Fu, Huei-Ting Tsai, Reina Haque, et al.

Journal of the American College of Cardiology|June 2, 2018

SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REALMatthew A Cavender, Anna Norhammar, Kåre I Birkeland, et al.

Circulation|May 20, 2017

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, et al.

Hematological Oncology|April 10, 2025

Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta-AnalysisLucio N Gordan, Rohan Medhekar, Alex Z Fu, et al.

Diabetes, Obesity & Metabolism|March 24, 2018

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL studyMikhail Kosiborod, Kåre I Birkeland, Matthew A Cavender, et al.

Clinical Lymphoma, Myeloma & Leukemia|October 14, 2023

Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review StudyLucio Navarro Gordan, Carlyn Rose Tan, Robert Vescio, et al.

Neuro-Oncology|April 14, 2022

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trialAntonio Omuro, Alba A Brandes, Antoine F Carpentier, et al.

Pageof 9